Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1951 NW 7th Ave, Ste 520 MIAMI FL 33136 |
Tel: | N/A |
Website: | https://www.longeveron.com |
IR: | See website |
Key People | ||
Joshua M. Hare Chairman of the Board, Co-Founder, Chief Science Officer | Wa'el Hashad Chief Executive Officer, Director | Donald M. Soffer Co-Founder, Director |
Lisa Locklear Chief Financial Officer, Executive Vice President | Paul Lehr General Counsel, Corporate Secretary, International Executive Director | Nataliya Agafonova Chief Medical Officer |
Business Overview |
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research. |
Financial Overview |
For the fiscal year ended 31 December 2023, Longeveron Inc revenues decreased 42% to $709K. Net loss applicable to common stockholders increased 18% to $22.2M. Revenues reflect Clinical trial revenue segment decrease of 29% to $668K, National Institutes of Health '�� Grant segment decrease of 75% to $41K. Higher net loss reflects General and administrative - Balancing increase of 48% to $10.5M (expense). |
Employees: | 23 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2.77M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.71M as of Mar 31, 2024 |
EBITDA (TTM): | -$19.89M as of Mar 31, 2024 |
Net annual income (TTM): | -$22.21M as of Mar 31, 2024 |
Free cash flow (TTM): | -$19.70M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 6,348,624 as of May 10, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |